1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Hemoglobin Testing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of chronic diseases and need for regular hemoglobin level monitoring
5.1.1.2. Availability of improved and user-friendly point-of-care testing
5.1.1.3. Government initiatives promoting awareness about anemia testing
5.1.2. Restraints
5.1.2.1. Complexity of certain testing methods and need for specialized skills
5.1.3. Opportunities
5.1.3.1. Technological advancements in hemoglobin testing methods
5.1.3.2. Introduction of high-performing home hemoglobin testing kits and devices
5.1.4. Challenges
5.1.4.1. Concerns associated with inaccuracy and false positives
5.2. Market Segmentation Analysis
5.2.1. Type: Use of cyanmethemoglobin method as a standard and cost-effective technique for measuring total hemoglobin concentration
5.2.2. Operation: Preference for non-invasive hemoglobin testing due to their convenience and ability to reduce discomfort associated with blood draws
5.2.3. Application: Advanced hemoglobin testing solutions to determine the severity of anemia
5.2.4. End-User: Availability of diverse range of hemoglobin testing to diagnose various hematological disorders
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Hemoglobin Testing Market, by Type
6.1. Introduction
6.2. Blood Glucose Testing
6.3. Cyanmethemoglobin Method
6.4. Hemoglobin A1c Testing
6.5. Hemoglobin Electrophoresis
7. Hemoglobin Testing Market, by Technology
7.1. Introduction
7.2. Laboratory Testing
7.3. Point-of-Care Testing
8. Hemoglobin Testing Market, by Operation
8.1. Introduction
8.2. Invasive Testing
8.3.1. Invasive Cuvette
8.3.2. Invasive Strip
8.3. Non-Invasive Testing
9. Hemoglobin Testing Market, by Application
9.1. Introduction
9.2. Anemia Diagnosis & Monitoring
9.3. Diabetes Diagnosis & Management
9.4. Sickle Cell Disease Screening
9.5. Thalassemia Detection
10. Hemoglobin Testing Market, by End-User
10.1. Introduction
10.2. Blood Bank
10.3. Diagnostic Laboratories
10.4. Homecare Settings
10.5. Hospitals & Clinics
10.6. Research Institutes
11. Americas Hemoglobin Testing Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Hemoglobin Testing Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Hemoglobin Testing Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. New Product Launch & Enhancement
14.3.1.1. Mylab Introduces Indigenous Point-of-Care Sickle Cell Anaemia Test
14.3.2. Investment & Funding
14.3.2.1. Hemex Health Awarded USD 3 Million Grant to Advance Commercialization of Gazelle Hb Variant Test for the U.S. market
14.3.3. Award, Recognition, & Expansion
14.3.3.1. Sanguina Receives US FDA Clearance for Haemoglobin Test Kit
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Abcam PLC
15.1.2. ACON Laboratories, Inc.
15.1.3. AdvaCare Pharma
15.1.4. Arkray, Inc.
15.1.5. ARUP Laboratories
15.1.6. Attikouris Enterprises Ltd.
15.1.7. Avantor, Inc.
15.1.8. Becton, Dickinson and Company
15.1.9. Bio-Rad Laboratories, Inc.
15.1.10. Bio-Techne Corporation
15.1.11. Boditech Med Inc.
15.1.12. Clarity Diagnostics, LLC
15.1.13. Cliawaived, Inc.
15.1.14. DiaSys Diagnostic Systems GmbH
15.1.15. EKF Diagnostics Holdings PLC by IBL PLC
15.1.16. F. Hoffmann-La Roche AG
15.1.17. HemoCue AB
15.1.18. Laboratory Corporation of America Holdings
15.1.19. Masimo Corp.
15.1.20. Merck KGaA
15.1.21. Nova Biomedical
15.1.22. OrSense Ltd.
15.1.23. PerkinElmer Inc.
15.1.24. Qiagen N.V.
15.1.25. Quest Diagnostics Incorporated
15.1.26. Siemens Healthcare GmbH
15.1.27. Sotera Health Company
15.1.28. Thermo Fisher Scientific Inc.
15.1.29. Versiti, Inc.
15.1.30. VivaChek Biotech (Hangzhou) Co., Ltd.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
